Gen2B
Alzheimer's disease, Frontotemporal dementia, Progressive supranuclear palsy
Pre-clinicalActive
Key Facts
Indication
Alzheimer's disease, Frontotemporal dementia, Progressive supranuclear palsy
Phase
Pre-clinical
Status
Active
Company
About Gen2 Neuroscience
Gen2 Neuroscience is a private, pre-clinical stage biotech targeting neurodegenerative diseases, particularly tauopathies like Alzheimer's disease. Its core strategy involves using human stem cell-derived models to understand disease propagation and to develop highly selective antibodies that block the uptake of extracellular, toxic tau while sparing normal tau. The company's lead program, Gen2B, aims to slow disease progression, and it has secured backing from the specialized Dementia Discovery Fund. Led by a small, experienced team, Gen2 is positioned in a high-need but challenging therapeutic area.
View full company profile